SHANDONG XINHUA (00719) applied for a drug registration certificate for the suspension of oseltamivir phosphate.

Shandong Xinhua (00719) announced that the company recently received the Drug Registration Certificate for the approval and issuance of the oseltamivir phosphate granules suspension by the National Medical Products Administration. This product is used for the treatment of type A and type B influenza in patients aged 2 weeks and older (oseltamivir phosphate can effectively treat type A and type B influenza, but there is not much clinical data on the use of type B influenza). Patients should use the product within 48 hours of the first appearance of symptoms. This product can also be used for the prevention of type A and type B influenza in individuals aged 1 year and older. The oseltamivir phosphate granules suspension submitted by Shandong Xinhua Pharmaceutical obtained the Drug Registration Certificate in December 2025, enriching the company's antiviral drug product line, and helping to enhance the company's overall competitiveness.